Because the early acquisition of a KRAS mutation triggers the adenoma-carcinoma sequence12, some malignant-potential IPMNs with different KRAS mutations from the adjacent LG-IPMN may develop into concomitant pancreatic cancer independently of the original IPMN. This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.